Lenalidomide Eg (Lenalidomide)

Lenalidomide binds to the cereblon protein, part of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s target specificity, leading to the degradation of transcription factors Ikaros and Aiolos. The resulting actions include anti‑angiogenic effects, modulation of immune cell activity, and direct inhibition of malignant cell growth.

The dose of Lenalidomide Eg is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the appropriate strength, schedule, and duration based on the specific indication, patient characteristics, and any relevant laboratory values.

Lenalidomide is classified as Pregnancy Category X because it has a high risk of causing fetal malformations and embryotoxicity. It is contraindicated during pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Safety during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the Lenalidomide Eg product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class, sharing a similar mechanism with thalidomide but offering greater potency and a more favorable safety profile, especially regarding peripheral neuropathy. Compared with conventional chemotherapy, Lenalidomide provides targeted immunomodulation and anti‑angiogenic effects, often resulting in improved response rates and tolerability in the approved hematologic cancers.

Lenalidomide Eg should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink. Ensure the packaging remains sealed until use to maintain product integrity.

Lenalidomide Eg is administered orally, typically as a tablet taken with water. The medication may be taken with or without food, depending on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and should not alter the timing or skip doses without medical advice.

The most serious risks include venous thromboembolism (blood clots), severe neutropenia or other cytopenias that increase infection risk, life‑threatening infections, second primary malignancies, and teratogenic effects that can cause fetal birth defects. Patients should be monitored regularly for signs of these events and seek immediate medical attention if they occur.

Lenalidomide Eg is contraindicated in pregnant women and in any individual who cannot use effective contraception during treatment. It should also be avoided in patients with known hypersensitivity to lenalidomide or any component of the formulation, and in those with uncontrolled severe infections or uncontrolled thrombotic disorders without appropriate prophylaxis.